The drug Osteogenone is often used in medical practice for the treatment of pathologies of the musculoskeletal system. Means in sufficient quantities contains trace elements – potassium and calcium, necessary for ensuring the processes of regeneration of bone tissue. Osteogenone is often prescribed to strengthen joints and bones. The drug is prescribed for the treatment of systemic osteoporosis. The drug component is well tolerated by patients of different age categories, however, there is a significant list of contraindications to use.
The main medicinal properties of the drug Osteogenon is the ability to inhibit the process of destruction of bone tissue. The drug is often used to restore the calcium-phosphorus balance. The composition is produced by pharmacological companies in the form of tablets intended for oral administration.
Description and composition
Osteogenone contains in its composition active substances and auxiliary components. Have the appearance of biconvex, oblong tablets of light yellow color.
The active substance is ossein-hydroxyapatite compound.
From the list of excipients emit:
- microcrystalline cellulose,
- colloidal silicon dioxide,
- magnesium stearate,
- potato starch.
The shell contains:
- titanium dioxide;
- iron oxide yellow.
A drug that has an effect on bone mineralization (regulator of calcium-phosphorus metabolism).
Osteogenone contains the elements necessary for the production of bone tissue and has a dual effect on the metabolism of bone tissue: it provides osteoblasts and inhibits osteoclasts.
Calcium is present in the preparation in the form of hydroxyapatite (in the ratio of phosphorus 2: 1), which ensures its complete isolation from the gastrointestinal tract. Inhibits the production of parathyroid hormone and prevents the destruction of bone tissue. Slow release of calcium from hydroxyapatite causes the absence of a peak of hypercalcemia.
Phosphorus, which is involved in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bone and stops its excretion by the kidneys.
Ossein is an organic component of the drug, which contains local bone tissue remodeling regulators (β-transforming growth factor, insulin-like growth factors I and II, osteocalcin, type 1 collagen), which activate the process of bone formation and stop bone resorption.
The β-transforming growth factor ensures the release of osteoblasts, increases their number, contributes to the production of collagen, and also stops the formation of osteoclast precursors.
Insulin-like growth factors I and II provide synthesis of osteocalcin production.
Osteocalcin improves the crystallization of bone tissue by combining calcium.
Collagen type 1 provides the formation of bone matrix.
Indications for use
The list of indications for use means include:
- primary osteoporosis, manifested under the influence of various external factors;
- treatment and prevention of secondary osteoporosis caused by rheumatoid arthritis;
- arresting the process of destruction that forms on the background of liver and kidney pathologies;
- osteoporosis that occurs on the background of thyroid disorders;
- diseases that appear on the background of the failure of the natural process of bone formation;
- restoration of phosphorus-calcium metabolism, disturbed during breastfeeding;
- joint dysplasia;
- rachitic deformation of the skeleton;
- reduction of the period of accretion of fractures.
If there are indications for use and no contraindications, the supplement is prescribed to patients. Doses are determined individually and can be adjusted during the entire course of drug treatment.
The drug can be prescribed to children of different ages as part of complex therapy to eliminate signs of osteoporosis. Often used in pediatric practice to combat congenital disorders of calcium-phosphorus metabolism.
for pregnant women and during lactation
Appointment during pregnancy and breastfeeding is possible in exceptional cases after receiving expert advice.
From the general list of contraindications that require limitations of the process of receiving funds emit:
- severe forms of renal failure;
- hemodialysis patients;
- urolithiasis disease;
- increased calcium in the human body;
- the drug is not recommended for use in pediatrics;
- increased patient susceptibility to the components of the drug.
Uses and doses
Osteogenone is taken orally. The dosage is determined in private by the attending specialist. The duration of the course of drug exposure is established after determining the susceptibility of the human body to the components of the tool.
Adult patients, subject to the absence of contraindications to the use of the drug is prescribed in a dose of up to 6 tablets per day. For the treatment of osteoporosis, the drug is used in a dose of not more than 4 tablets per day. This volume is divided into 2 doses.
Data on the use of the drug in pediatric practice – not available. If there are important indications, the dose is adjusted individually depending on the age of the patient and his weight.
for pregnant women and during lactation
During pregnancy and breastfeeding, the composition is used to replenish the reserves of calcium and phosphorus in the body. The permissible dosage does not exceed 2 tablets per day, this volume is divided into 2 doses.
Information regarding serious complaints arising from the patient when using the drug is not recorded. Possible manifestation of acute allergic reactions. With the manifestation of these side effects should consult a doctor. The specialist will adjust the dose and establish the optimal treatment regimen.
Interaction with other drugs
The drug reduces the absorption of iron components, bisphosphonates and antibiotics of the tetracycline group, therefore, when used together with these substances, the time interval between their consumption should be at least 4 hours.
With simultaneous use of osteogenone with vitamin D or thiazide diuretics, a specialist needs to evaluate the likelihood of the risk of hypercalcemia due to increased calcium resorption.
In patients with a predisposition to urolithiasis, it may be necessary to adjust the dosage regimen of the substance, depending on the performance of laboratory tests.
In patients with impaired renal function, prolonged use of significant doses of the substance should be avoided.
The composition of the drug includes only residual amounts of sodium chloride, therefore, it is acceptable to use Osteogenon in patients with arterial hypertension.
Patients taking Osteogenon should strictly comply with the dosage. The main side effect that can worsen the result is hypercalcemia. The following symptoms may occur:
Laboratory tests are required to confirm an overdose.
The drug should be kept out of the reach of children at a temperature not exceeding 30 degrees. The product must be stored in its original packaging. Observing the moisture regime. The maximum storage time is no more than 4 years.
Currently there are no analogues on the active substance. A substitute can be selected by a specialist after careful consideration of the indications for use from the following list:
- Calcimax. This is a biologically active complex, which is produced in capsules. It contains minerals that are involved in the formation of bones, connective and nervous tissue. It prevents the occurrence of osteoporosis, is used to treat chronic pathologies of the musculoskeletal system, which are accompanied by inflammation. Prescribed to his adult patients.
- Growth-Norm. Homeopathic remedy, produced in granules. It regulates the exchange of minerals in the body, stimulates the formation of bone tissue during the period of intensive growth, with fractures, has anti-inflammatory effect. Can be used in children under 1 year.
Independently replace the drug analogue is prohibited. Before replacing you need to consult a doctor.
The cost of Osteogenone is on average 689 rubles. Prices range from 565 to 850 rubles.